A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors

Human Molecular Genetics

Volumn 8, Issue 1, 1999, Pages 35-44

  Li, Cuiling ^a   Chen, Lin ^a   Iwata, Tomoko ^b   Kitagawa, Motoo ^c   Fu, Xin Yuan ^c   Deng, Chu Xia ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; GLUTAMIC ACID; LYSINE; PROTEIN P16; STAT1 PROTEIN; STAT5 PROTEIN; STAT5B PROTEIN;

ACHONDROPLASIA; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DYSPLASIA; BONE GROWTH; CARTILAGE; CARTILAGE CELL; DWARFISM; ENCHONDRAL OSSIFICATION; FEMUR; GROWTH PLATE; LONG BONE; MACROCEPHALY; MOUSE; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; ANIMALS; BASE SEQUENCE; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA PRIMERS; DNA-BINDING PROTEINS; DWARFISM; GENE EXPRESSION; HETEROZYGOTE; HOMOZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MILK PROTEINS; PHENOTYPE; POINT MUTATION; PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

ANIMALIA; MURINAE;

EID: 0032938128     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/8.1.35     Document Type: Article

References (49)

1. Martin, G.R. (1998) The roles of FGFs in the early development of vertebrate limbs. Genes Dev., 12, 1571-1586.
2. Thompson, L.M., Raffioni, S., Wasmuth, J.J. and Bradshaw, R.A. (1997) Chimeras of the native form or achondroplasia mutant (G375C) of human fibroblast growth factor receptor 3 induce ligand-dependent differentiation of PC12 cells. Mol. Cell. Biol., 17, 4169-4177.
3. Rousseau, F. Bonaventure, J., Legeai-Mallet, L., Pelet, A., Rozet, J.M., Maroteaux, P., Le Merrer, M. and Munnich, A. (1994) Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature, 371, 252-254.
4. Shiang, R., Thompson, L.M., Zhu, Y.Z., Church, D.M., Fielder, T.J., Bocian, M., Winokur, S.T. and Wasmuth, J.J. (1994) Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell, 78, 335-342.
5. Tavormina, P.L., Shiang, R., Thompson, L.M., Zhu, Y.Z., Wilkin, D.J., Lachman, R.S., Wilcox, W.R., Rimoin, D.L., Cohn, D.H. and Wasmuth, J.J. (1995) Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nature Genet., 9, 321-328.
6. Bellus, G.A., McIntosh, I., Smith, E.A., Aylsworth, A.S., Kaitila, I., Horton, W.A., Greenhaw, G.A., Hecht, J.T. and Francomano, C.A. (1995) A recurrent mutation in the tyrosinc kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nature Genet., 10, 357-359.
7. Orioli, I.M., Castilla, E.E. and Barbosa-Neto, J.G. (1986) The birth prevalence rates for the skeletal dysplasias. J. Med. Genet., 23, 328-332.
8. Rousseau, F., Bonaventure, J., Le Merrer, M., Maroteaux, P. and Munnich, A. (1996) [Mutations of FGFR3 gene cause 3 types of nanisms with variable severity: achondroplasia, thanatophoric nanism and hypochondroplasia]. Ann. Endocrinol. (Paris), 57, 153.
9. Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A. and Leder, P. (1996) Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell, 84, 911-921.
10. Colvin, J.S., Bohne, B.A., Harding, G.W., McEwen, D.G. and Ornitz, D.M. (1996) Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nature Genet., 12, 390-397.
11. Naski, M.C., Wang, Q., Xu, J. and Ornitz, D.M. (1996) Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nature Genet., 13, 233-237.
12. Webster, M.K. and Donoghue, D.J. (1996) Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J., 15, 520-527.
13. Webster, M.K., D'Avis, P.Y. Robertson, S.C. and Donoghue, D.J. (1996) Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol. Cell. Biol., 16, 4081-4087.
14. Su, W.C., Kitagawa, M., Xue, N., Xie, B., Garofalo, S., Cho, J., Deng, C., Horton, W.A. and Fu, X.Y. (1997) Activation of Statl by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature, 386, 288-292.
15. Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K. and Elledge, S.J. (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805-816.
16. el-Deiry, W.S., Tokino, T. Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W. and Vogelstein, B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
17. Brugarolas, J., Chandrasekaran, C., Gordon, J.I., Beach, D., Jacks, T. and Hannon, G.J. (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature, 377, 552-557.
18. Deng, C., Zhang, P., Harper, J.W., Elledge, S.J. and Leder, P. (1995) Mice lacking p21C1P1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 82, 675-684.
19. Sheikh, M.S., Rochefort, H. and Garcia, M. (1995) Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene, 11, 1899-1905.
20. Ornitz, D.M. and Leder, P. ( 1992) Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. J. Biol. Chem., 267, 16305-16311.
21. Yang, X., Li, C., Xu, X. and Deng, C. (1998) The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc. Natl Acad. Sci. USA, 95, 3667-3672.
22. Lakso, M., Pichel, J.G., Gorman, J.R., Sauer, B., Okamoto, Y., Lee, E., Alt, F.W. and Westphal, H. (1996) Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc. Natl Acad. Sci. USA, 93, 5860-5865.
23. Schindler, C., Shuai, K., Prezioso, V.R. and Darnell, J.E. Jr (1992) Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science, 257, 809-813.
24. Fu, X.Y. and Zhang, J.J. (1993) Transcription factor p91 interacts with the epidermal growth factor receptor and mediates activation of the c-fos gene promoter. Cell, 74, 1135-1145.
25. Delezoide, A.L., Lasselin-Benoist, C., Legeai-Mallet, L., Brice, P., Senee, V., Yayon, A., Munnich, A., Vekemans, M. and Bonaventure, J. (1997) Abnormal FGFR 3 expression in cartilage of thanatophoric dysplasia fetuses. Hum. Mol. Genet., 6, 1899-1906.
26. Horton, W.A. (1997) Fibroblast growth factor receptor 3 and the human chondrodysplasias. Curr. Opin. Pediatr., 9, 437-442.
27. Muenke, M. and Schell, U. (1995) Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet., 11, 308-313.
28. Mulvihill, J.J. (1995) Craniofacial syndromes: no such thing as a single gene disease. Nature Genet. 9, 101-103. [Erratum. Nature Genet. (1995) 9, 451.]
29. Lewanda, A.F., Meyers, G.A. and Jabs, E.W. (1996) Craniosynostosis and skeletal dysplasias: fibroblast growth factor receptor defects. Proc. Assoc. Am. Physicians, 108, 19-24.
30. Webster, M.K. and Donoghue, D.J. (1997) FGFR activation in skeletal disorders: too much of a good thing. Trends Genet., 13, 178-182.
31. Arman, E., Haffner-Krausz, R., Chen, Y., Heath, J.K. and Lonai, P. (1998) Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian development. Proc. Natl Acad. Sci. USA, 95, 5082-5087.
32. Deng, C., Bedford, M., Li, C., Xu, X., Yang, X., Dunmore, J. and Leder, P. (1997) Fibroblast growth factor receptor-1 (FGFR-1) is essential for normal neural tube and limb development. Dev. Biol., 185, 42-54.
33. Deng, C.X., Wynshaw-Boris, A., Shen, M.M., Daugherty, C., Ornitz, D.M. and Leder, P. (1994) Murine FGFR-I is required for early postimplantation growth and axial organization. Genes Dev., 8, 3045-3057.
34. Xu, X., Weinstein, M., Li, C., Naski, M., Cohen, R.I., Ornitz, D.M., Leder, P. and Deng, C. (1998) Fibroblast growth factor receptor 2 (FGFR2)-mediated reciprocal regulation loop between FGF8 and FGF10 is essential for limb induction. Development, 125, 753-765.
35. Yamaguchi, T.P., Harpal, K., Henkemeyer, M. and Rossant, J. (1994) fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation. Genes Dev., 8, 3032-3044.
36. Bellus, G.A., McIntosh, I., Szabo, J., Aylsworth, A., Kaitila, I. and Francomano, C.A. (1996) Hypochondroplasia: molecular analysis of the fibroblast growth factor receptor 3 gene. Ann. Acad. Sci. 785, 182-187.
37. Hecht, J.T., Francomano, C.A., Horton, W.A. and Annegers, J.F. (1987) Mortality in achondroplasia. Am. J. Hum. Genet., 41, 454-464.
38. McKusick, V.A., Kelly, T.E. and Dorst, J.P. (1973) Observations suggesting allelism of the achondroplasia and hypochondroplasia genes. J. Med. Genet., 10, 11-16.
39. van der Geer, P., Hunter, T. and Lindberg, R.A. ( 1994) Receptor protein-tyrosine kinases and their signal transduction pathways. Ann. Rev. Cell. Biol., 10, 251-337.
40. Reimold, A.M., Grusby, M.J., Kosaras, B., Fries, J.W., Mori, R., Maniwa, S., Clauss, I.M., Collins, T. Sidman, R.L., Glimcher, M.J. and Glimcher, L.H. (1996) Chondrodysplasia and neurological abnormalities in ATF-2-deficient mice. Nature, 379, 262-265.
41. Karaplis, A.C., Luz, A., Glowacki, J., Bronson, R.T., Tybulewicz, V.L., Kronenberg, H.M. and Mulligan, R.C. (1994) Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev., 8, 277-289.
42. Weir, E.C., Philbrick, W.M., Amling, M., Neff, L.A., Baron, R. and Broadus, A.E. (1996) Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation. Proc. Natl Acad. Sci. USA, 93, 10240-10245.
43. Karaplis, A.C. and Vautour, L. (1997) Parathyroid hormone-related peptide and the parathyroid hormone/parathyroid hormone-related peptide receptor in skeletal development. Curr. Opin. Nephrol. Hypertension, 6, 308-313.
44. Amizuka, N., Warshawsky, H., Henderson, J.E., Goltzman, D. and Karaplis, A.C. (1994) Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J. Cell. Biol., 126, 1611-1623.
45. Vortkamp, A., Lee, K., Lanske, B., Segre, G.V., Kronenberg, H.M. and Tabin, C.J. (1996) Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science, 273, 613-622.
46. Legeai-Mallet, L., Benoist-Lasselin, C., Delezoide, A.L., Munnich, A. and Bonaventure, J. (1998) Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. J. Biol. Chem., 273, 13007-13014.
47. Perez-Castro, A.V., Wilson, J. and Altherr, M.R. (1995) Genomic organization of the mouse fibroblast growth factor receptor 3 (Fgfr3) gene. Genomics, 30, 157-162.
48. McLeod, M.J. (1980) Differential staining of cartilage and bone in whole mouse fetuses by alcian blue and alizarin red S. Teratology, 22, 299-301.
49. Franklin, D.S. and Xiong, Y. (1996) Induction of p18INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation. Mol. Biol. Cell, 7, 1587-1599.